Welcome to the e-CCO Library!

DOP75: Effectiveness and Safety of tofacitinib versus vedolizumab in Patients with Ulcerative Colitis; A Nationwide, ICC Registry study
Year: 2022
Source: ECCO'22
Authors: Straatmijer , T.(1);Visschedijk , M.(2);de Vries , A.(3);Hoentjen , F.(21);van Bodegraven , A.A.(5);Bodelier , A.G.L.(6);de Boer , N.K.H.(7);Dijkstra , G.(2);Festen , E.A.M.(2);Horjus , C.(8);Jansen , J.M.(9);Jharap , B.(10);Mares , W.(11);Oldenburg , B.(12);Ponsioen , C.Y.(13);Romkens , T.E.H.(14);Srivastava , N.(15);van der Voorn , M.M.(16);West , R.L.(17);van der Woude , J.C.(3);Wolvers , M.D.J.(18);Pierik , M.(19);van der Meulen , A.E.(20);Duijvestein , M.(4);
Created: Friday, 11 February 2022, 3:52 PM
DOP75: Loss-of-response and immunogenicity following immunomodulator withdrawal from anti-tumour necrosis factor alpha combination therapy: Results from a large retrospective cohort study
Year: 2021
Source: ECCO'21 Virtual
Authors: Mahmoud, R.(1);Schultheiss, J.(1);Louwers, J.(1);van der Kaaij, M.(1);van Hellemondt, B.(1);Mahmmod, N.(2);van Boeckel, P.(2);Jharap, B.(3);Fidder, H.(1);Oldenburg, B.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP75: Surgery and hospitalisations rates in inflammatory bowel disease patients in the Québec provincial database from 199–6 to 2015
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Verdon*1, J. Reinglas1, J. Coulombe2, L. Gonczi3, T. Bessissow1, W. Afif1, M. Vutcovici4, G. Wild1, E. Seidman1, A. Bitton1, P. Brassard5,6, P. Lakatos1

Created: Friday, 22 February 2019, 9:41 AM
DOP75: Video capsule endoscopy may detect active small bowel Crohn's disease requiring change of treatment despite unremarkable ileo-colonic anastomosis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Thurm, T.(1,2)*;Zmora, N.(1,2,3);Hirsh, A.(1,2);Deutsch, L.(1,2);Maharshak, N.(1,2);
Created: Friday, 14 July 2023, 10:43 AM
DOP76 Corticosteroid sparing effects of ustekinumab therapy for ulcerative colitis through 2 years: UNIFI long-term extension
Year: 2020
Source:

ECCO'20 Vienna

Authors:

L. Peyrin-Biroulet1, W. Sandborn2, B. Sands3, E. Scherl4, C. Marano5, C. O’Brien5, H. Zhang6, J. Johanns6, Y. Zhou6, M. Abreu7, R.P. Arasaradnam8, D.S. Rowbotham9, R.W.L. Leong10, S. Danese11, UNIFI Investigators

Created: Thursday, 30 January 2020, 10:12 AM
DOP76: Comparison of healing of complex perianal Crohn´s disease fistulas by advancement flap and mesenchymal stem cell therapy
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Serclova, Z.(1)*;Tremerova, A.(2);Lengalova, M.(2);Petra, Z.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP76: No durable impact of COVID-19 on disease activity and microbiome composition in patients with IBD
Year: 2021
Source: ECCO'21 Virtual
Authors: Funez-dePagnier, G.(1);Lima, S.(1);Duenas-Bianchi, L.(1);Lai, D.(1);Ahmed, W.(1);Battat, R.(1);Scherl, E.(1);Lukin, D.(1);Longman, R.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP76: Prevalence and healthcare costs of perianal fistulas in Crohn’s disease in a nationwide cohort
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Nordholm-Carstensen*1, N. Qvist2, B. Højgaard3, C. Halling3, M. Carstensen4, N-P. Ipland4, J. Burisch5

Created: Friday, 22 February 2019, 9:41 AM
DOP76: Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent
Year: 2022
Source: ECCO'22
Authors: Buisson, A.(1);Nachury, M.(2);Fumery, M.(3);Guilmoteau, T.(1);Leclerc, E.(1);Altwegg, R.(4);Serrero, M.(5);Mathieu, N.(6);Treton, X.(7);Vuitton, L.(8);Pereira, B.(9);Amiot, A.(10);Bouguen, G.(11);
Created: Friday, 11 February 2022, 3:52 PM
DOP77 Ustekinumab is associated with better effectiveness outcomes when compared with vedolizumab in Crohn’s disease patients with prior anti-TNF failure: comparative effectiveness study from the ICC Registry
Year: 2020
Source:

ECCO'20 Vienna

Authors:

V. Biemans drs1, J. van der Woude2, G. Dijkstra3, A. van der Meulen- de Jong4, M. Löwenberg5, N. de Boer6, B. Oldenburg7, N. Srivastava8, J. Jansen9, A. Bodelier10, R. West11, A. de Vries2, J. Haans12, D. de Jong13, F. Hoentjen13, M. Pierik12, on behalf of the Dutch Initiative on Crohn and Colitis (ICC)

Created: Thursday, 30 January 2020, 10:12 AM
DOP77: Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naïve patients with Crohn´s Disease with Propensity Score adjustment: Maintenance phase results at week-52 from the prospective VEDOIBD study
Year: 2022
Source: ECCO'22
Authors: Di Giuseppe, R.(1);Plachta-Danielzik, S.(2);Bokemeyer, B.(3);Efken, P.(4);Mohl, W.(5);Hoffstadt, M.(6);Krause, T.(7);Schweitzer, A.(8);Schnoy, E.(9);Atreya, R.(10);Teich, N.(11);Trentmann, L.(12);Ehehalt, R.(13);Franzenburg, S.(2);Hartmann, P.(4);Schreiber, S.(14);
Created: Friday, 11 February 2022, 3:52 PM
DOP77: Effect of Inflammatory Bowel Disease and Related Medications on COVID-19 Incidence, Disease Severity, and Outcome -The Israeli Experience
Year: 2021
Source: ECCO'21 Virtual
Authors: Richter, V.(1);Bermont, A.(1);Cohen, D.L.(1);Broide, E.(1);Shirin, H.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP77: Is durable remission achievable after ileocolic resection for Crohn's disease ? Long-term results of a prospective multicentric cohort study of the GETAID Chirurgie
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Abdalla, S.(1)*;Benoist, S.(1);Maggiori, L.(2);Lefevre, J.(3);Denost, Q.(4);Cotte, E.(5);Germain, A.(6);Beyer-Berjot, L.(7);Desfourneaux, V.(8);Rahili, A.(9);Duffas, J.P.(10);Pautrat, K.(11);Denet, C.(12);Bridoux, V.(13);Meurette, G.(14);Faucheron, J.L.(15);Loriau, J.(16);Souche, F.R.(17);Corte, H.(2);Zerbib, P.(18);Panis, Y.(19);Brouquet, A.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP77: The effectiveness of combination therapy mesenchymal stromal cells and certolizumab pegol in perianal lesions in Crohn's disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

O. Knyazev1, A. Kagramanova*1, A. Lishchinskaya1, M. Zvyaglova1, D. Kulakov1, A. Parfenov1

Created: Friday, 22 February 2019, 9:41 AM
DOP78 Intestinal surgery rates in ulcerative colitis and Crohn’s disease in the era of biologics: A Danish Nationwide Register Study from 2003 to 2016
Year: 2020
Source:

ECCO'20 Vienna

Authors:

K. Vadstrup1, S. Alulis2, A. Borsi3, J. Olsen4, T.R. Jørgensen5, P. Munkholm6, N. Qvist7

Created: Thursday, 30 January 2020, 10:12 AM
DOP78: Comparative study of the effectiveness of vedolizumab versus ustekinumab after anti-TNF failure (VERSUS-CD)
Year: 2022
Source: ECCO'22
Authors: García García, M.J.(1);Rivero, M.(1);Fernández-Clotet, A.(2);de Francisco, R.(3);Sicilia, B.(4);Mesonero, F.(5);de Castro, M.L.(6);Casanova, M.J.(7);Bertoletti, F.(8);García Alonso, F.J.(9);López García, A.(10);Julián, B.(11);Calvet, X.(12);Barreiro-de Acosta, M.(13);Jara, L.(14);Varela, P.(15);Nuñez, A.(16);Ricart, E.(2);Riestra, S.(3);Arias, L.(4);Rodríguez, M.(17);Arranz, L.(18);Pajares, R.(19);Mena, R.(20);Calafat, M.(21);Camo, P.(22);Jiménez, L.(23);Ponferrada, A.(24);Madrigal, R.E.(25);Llao, J.(26);Sesé, E.(27);Almela, P.(28);Codesido, L.(29);de la Maza, S.(30);Leal, C.(31);Sánchez, E.(5);Pineda Mariño, J.R.(6);Domènech, E.(21);Chaparro, M.(7);P. Gisbert, J.(7); GETECCU
Created: Friday, 11 February 2022, 3:52 PM
DOP78: Does KONO-S anastomosis reduce recurrence in Crohn's disease compared to conventional ileocolonic anastomosis ? A nationwide propensity score-matched study from GETAID Chirurgie Group (KoCoRICCO study).
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Alibert, L.(1);Betton, L.(2);Falcoz, A.(3);Manceau, G.(4);Benoist, S.(5);Zerbib, P.(6);Podevin, J.(7);Maggiori, L.(8);Brouquet, A.(5);Tyrode, G.(9);Vuitton, L.(9);Vernerey, D.(3);Lefevre, J.(2);Lakkis, Z.(1)*;
Created: Friday, 14 July 2023, 10:43 AM
DOP78: Efficacy of vedolizumab in perianal Crohn’s disease: the BioLAP multi-centre observational study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Biron*1, P. Seksik2, M. Nachury3, S. Nancey4, Y. Bouhnik5, M. Serrero6, L. Armengol-Debeir7, A. Buisson8, M-L. Tran Minh9, C. Zallot10, M. Fumery11, G. Bouguen12, V. Abitbol13, S. Viennot14, E. Chanteloup15, S. Rajca16, N. Dib17, L. Peyrin-Biroulet10, L. Vuitton18

Created: Friday, 22 February 2019, 9:41 AM
DOP78: The differential diagnosis and clinicopathological spectrum of Inflammatory Bowel Disease: An interesting and informative ECCO topical review
Year: 2021
Source: ECCO'21 Virtual
Authors: Feakins , R.M.(1); Torres, J.(2); Borralho-Nunes, P.(3,4); Burisch, J.(5); Cúrdia Gonçalves, T.(6,7,8); De Ridder, L.(9); Driessen, A.(10); Lobatón, T.(11); Menchén, L.(12,13,14); Mookhoek, A.(15); Noor, N.(16); Svrcek, M.(17); Villanacci, V.(18); Zidar, N.(19); Tripathi, M.(20)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP79 Dose escalation of upadacitinib in Crohn’s disease patients with an inadequate response: Data from the randomised CELEST study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

W. Sandborn MD1, J. Panés2, L. Peyrin-Biroulet3, E. Louis4, S. Greenbloom5, W. Zhou6, Q. Zhou7, J. Liu8, A.P. Lacerda6

Created: Thursday, 30 January 2020, 10:12 AM